RMC No. 4-2019 publishes the FDA list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs for pharmacy and healthcare VAT compliance.

Pharmacies, hospitals, drug distributors, and VAT-registered sellers of medicine must treat the FDA-identified drugs for diabetes, high cholesterol, and hypertension as VAT-exempt once covered by the published FDA list. RMC No. 4-2019 matters because the VAT treatment of commonly prescribed maintenance medicines is no longer merely a general statutory exemption; it is tied to the official list issued by the Food and Drug Administration under Joint Administrative Order No. 2-2018. Businesses selling these medicines must therefore review their product master files, point-of-sale systems, invoices, and VAT reporting treatment to avoid charging output VAT on medicines that fall within the published VAT-exempt list.

What RMC No. 4-2019 Changed

RMC No. 4-2019, dated January 10, 2019, publishes the full text of the letter from the Food and Drug Administration containing the list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs. The circular was issued pursuant to Joint Administrative Order No. 2-2018, which provides the implementing guidelines on the value-added tax exemption of the sale of drugs prescribed for diabetes, high cholesterol, and hypertension under Republic Act No. 8424, otherwise known as the National Internal Revenue Code of 1997, as amended by Republic Act No. 10963.

The key operational change is that covered sellers must look to the FDA list when determining whether a drug for diabetes, high cholesterol, or hypertension should be treated as VAT-exempt. For business owners and accounting teams, this is a product-level VAT classification issue. It is not enough to classify all medicine sales in the same way, and it is also not enough to rely only on the general disease category of the drug. The RMC points taxpayers to the FDA-issued list as the controlling reference for the drugs covered by the exemption.

For customers, the practical effect is that the sale of qualifying listed medicines should not be subjected to 12% VAT. For sellers, the practical effect is that pricing, official receipts or invoices, inventory coding, POS configuration, and VAT return preparation must distinguish between VATable medicines and VAT-exempt medicines covered by the FDA list.

Who Is Affected

The most directly affected businesses are pharmacies, drugstores, hospital pharmacies, clinics with medicine sales, drug wholesalers, distributors, and retailers that sell prescription drugs for diabetes, high cholesterol, and hypertension. VAT-registered taxpayers engaged in the sale of medicines must pay particular attention because the error can affect output VAT reporting, invoice presentation, and customer pricing.

Corporate accountants, CFOs, and tax managers of healthcare groups should also review RMC No. 4-2019 because the exemption affects revenue classification. A medicine sale that is VAT-exempt should be treated differently from a VATable sale in the books and in VAT filings. This is especially important for businesses with high medicine turnover, multiple branches, or centralized inventory systems where product tax codes are applied across locations.

Patients and employers with healthcare benefit programs may also be indirectly affected. Although the RMC is directed to internal revenue officials, employees, and others concerned, the commercial consequence is felt at the transaction level. Where the drug is in the FDA-published list, the VAT exemption can affect the final selling price of maintenance medicines commonly used for diabetes, hypertension, and high cholesterol.

Key Compliance Requirements and Deadlines

RMC No. 4-2019 is dated January 10, 2019. It states that the FDA letter is also dated January 10, 2019 and that the list was issued in compliance with Joint Administrative Order No. 2-2018. The circular itself does not state a separate future transition deadline, grace period, or delayed effectivity date. Because the issuance was made for the information and guidance of all concerned, covered taxpayers should treat the published list as an immediate compliance reference from the issuance date unless a later applicable BIR or FDA issuance provides otherwise.

The principal compliance step is to identify whether the medicine being sold is included in the FDA list of VAT-exempt drugs for diabetes, high cholesterol, and hypertension. Once identified, the taxpayer should ensure that the sale is recorded as VAT-exempt, not VATable. This requires coordination between tax, finance, sales, procurement, inventory, and IT teams.

Businesses should also preserve documentation showing how the VAT treatment was determined. For pharmacies and drug distributors, this may include the relevant FDA list, internal product mapping, SKU-level tax classification approvals, and system screenshots showing the VAT code assigned to each covered product. For corporate taxpayers operating multiple branches, consistent implementation is important because one branch charging VAT while another branch treats the same listed drug as VAT-exempt can create pricing, reporting, and audit exposure.

Penalties and Risks for Non-Compliance

RMC No. 4-2019 does not create a special penalty schedule for misclassifying covered medicines. It does not state a separate fine, surcharge, interest rate, or compromise penalty for failure to follow the published FDA list. However, the absence of a special penalty in the circular does not make the classification optional.

The tax risk arises from incorrect VAT treatment. If a covered drug is wrongly treated as VATable, the seller may overcharge customers and misstate VAT reporting. If a non-covered drug is wrongly treated as VAT-exempt, the seller may understate output VAT. In either case, the business may need to correct its invoices, accounting entries, VAT returns, and customer pricing treatment depending on the nature of the error and the applicable tax rules.

For regulated healthcare sellers, there is also a practical audit risk. The circular specifically enjoins all concerned to be guided accordingly and to give the circular wide publicity. That language signals that BIR personnel and affected taxpayers are expected to apply the VAT exemption based on the published FDA list. A taxpayer that ignores the list or fails to update its system may have difficulty defending a contrary VAT treatment during a BIR review.

Practical Steps for Pharmacies, Hospitals, and Drug Sellers

First, businesses should obtain and maintain the FDA list referenced in RMC No. 4-2019 and compare it against their actual drug inventory. The review should be done at the product level, not merely by therapeutic category. Drugs prescribed for diabetes, high cholesterol, and hypertension should be checked against the published list before assigning VAT treatment.

Second, accounting and IT teams should update POS systems, billing software, inventory databases, and enterprise resource planning systems so that covered drugs are tagged as VAT-exempt. This is the most important operational step because manual correction at the cashier or invoicing level is prone to error, especially for businesses with multiple branches and high transaction volumes.

Third, finance teams should review official receipts, invoices, sales reports, VAT returns, and internal tax reports to ensure that sales of listed medicines are not included as VATable sales. The VAT-exempt classification should be visible in the seller’s accounting records and supported by the product mapping.

Fourth, procurement and compliance teams should monitor later updates from the FDA and BIR. RMC No. 4-2019 publishes the FDA list existing under the January 10, 2019 FDA letter. If later FDA lists or BIR circulars update the covered medicines, businesses should revise their tax coding promptly.

Fifth, management should assign responsibility for maintaining the VAT-exempt drug database. This should not be left solely to cashiers or branch personnel. A central tax or finance officer should approve changes to VAT codes, especially when new medicine SKUs are added.

Why This Matters for BIR Compliance

RMC No. 4-2019 is a short issuance, but it has significant day-to-day consequences for businesses selling maintenance medicines. The most searched practical questions are whether diabetes drugs are VAT-exempt in the Philippines, whether hypertension medicine is subject to VAT, whether high-cholesterol drugs are VAT-exempt, and how pharmacies should apply the BIR FDA VAT-exempt drug list. The answer depends on whether the product is within the FDA-published list referenced by the BIR.

For CFOs and accountants, the compliance issue is not theoretical. VAT treatment affects pricing, receipts, VAT returns, revenue reports, and audit defense. A business that sells medicines without a reliable SKU-level VAT classification process may create recurring errors across thousands of transactions.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco assists Philippine businesses with BIR compliance, VAT classification, tax audit preparation, healthcare regulatory issues, and documentation of tax positions. For pharmacies, hospitals, healthcare providers, and distributors, we can help review product-level VAT treatment, align invoicing practices with BIR issuances, and prepare practical compliance protocols for branch-level implementation.

If your business sells diabetes, high-cholesterol, or hypertension drugs and needs guidance on RMC No. 4-2019, VAT-exempt medicine classification, or BIR audit readiness, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *